Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain

World News: . []

DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) --  (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid (CBD) therapeutics, announced today that it has further elucidated the mechanism of action (MOA) of its leading investigative drug candidate KLS-13019, a CBD-like molecule for the potential treatment of neuropathic pain. Through extensive pre-clinical testing and under a NIH-NIDA Phase 1 grant study, Kannalife has identified a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN). Under the recently completed NIH-NIDA Phase 1 grant study, Kannalife’s research has shown that its leading drug candidate KLS-13019 plays an important role in the regulation of mNCX-1, an important pharmacological target in the prevention and in-part reversal of CIPN in the pre-clinical animal model. In comparison with CBD and morphine, KLS-13019 stood out as a viable drug candidate that out-performed CBD and poses as a viable alternative to the use of opioids as the frontline current standard of care for patients suffering from CIPN.

Chemotherapy-induced peripheral neuropathy is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited. Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.

“There is a tremendous unmet patient need when it comes to treating neuropathic pain disorders, particularly CIPN. We believe we are on the forefront of a breakthrough in non-opioid alternatives for the treatment of chronic pain management, for which KLS-13019 represents a potential new non-addictive option with greater selectively and a wider therapeutic window of use. The target mNCX-1 is just part of the big story here. Stay tuned,” stated Dean Petkanas, CEO of Kannalife.

The global market for neuropathic pain was valued at more than $5 Billion in 2015, and in 2016, CIPN accounted for more than 42% of market revenue. It’s estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 Billion.

To further bring to life the MOA of KLS-13019 as well as Kannalife’s data-driven, scientific approach to the discovery of CBD-like molecules, the Company has launched a new animated video via Vimeo at . Through its research and development efforts over the past decade, the Company has established an intellectual property estate specific to the formulation of these CBD-like compounds.

Additional scientific details of the MOA as well as the protective effects of CBD and KLS-13019 against CIPN toxicity have been published in the in a paper titled, “.”

The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.

Andrew Hard, 888-829-0070 andrew.hard@cmwmedia.com

Mike Mulvihill, 804-334-2292 mike.mulvihill@padillaco.com

A video accompanying this announcement is available at:

More news and information about Kannalife, Inc.

Published By:

Globe Newswire: 14:00 GMT Tuesday 14th January 2020

Published: .

Search for other references to "kannalife" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us